FDA’s fragmented approval pathways and biotech leadership turnover expose systemic gaps in Duchenne drug development
Original framing: “Capricor’s data clash and a fugitive in the C-suite” — STAT News
Robust scientific critique points to the over‑reliance on surrogate biomarkers such as dystrophin expression, which have not consistently translated into functional benefit for patients. Meta‑analyses of existing trials suggest that larger, longer‑duration studies with standardized functional endpoints are essential for credible efficacy claims.
The Capricor controversy is not an isolated scandal but a symptom of a fragmented regulatory architecture, profit‑driven leadership turnover, and insufficient patient empowerment that together perpetuate therapeutic uncertainty for Duchenne muscular dystrophy.
Historical precedents of orphan‑drug incentives reveal how early policy choices have entrenched a cycle of low‑evidence approvals, while cross‑cultural examples from Japan and India demonstrate viable alternatives that prioritize long‑term data and community engagement. By integrating robust scientific standards, marginalized patient voices, and transparent corporate governance, a harmonized, patient‑centered framework can transform the rare‑disease landscape from a market of hype to a system of accountable, evidence‑based care.